These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16406421)
21. A polymorphic tetranucleotide repeat in the CYP19 gene and male breast cancer. Young IE; Kurian KM; MacKenzie MA; Kunkler IH; Cohen BB; Hooper ML; Wyllie AH; Steel CM Br J Cancer; 2000 Apr; 82(7):1247-8. PubMed ID: 10755395 [TBL] [Abstract][Full Text] [Related]
22. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Kristensen VN; Andersen TI; Lindblom A; Erikstein B; Magnus P; Børresen-Dale AL Pharmacogenetics; 1998 Feb; 8(1):43-8. PubMed ID: 9511180 [TBL] [Abstract][Full Text] [Related]
23. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304 [TBL] [Abstract][Full Text] [Related]
24. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674 [TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327 [TBL] [Abstract][Full Text] [Related]
26. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Thyagarajan B; Brott M; Mink P; Folsom AR; Anderson KE; Oetting WS; Gross M Cancer Lett; 2004 Apr; 207(2):183-9. PubMed ID: 15072827 [TBL] [Abstract][Full Text] [Related]
27. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Suspitsin EN; Grigoriev MY; Togo AV; Kuligina ES; Belogubova EV; Pozharisski KM; Chagunava OL; Sokolov EP; Theillet C; Berstein LM; Hanson KP; Imyanitov EN Eur J Cancer; 2002 Sep; 38(14):1911-6. PubMed ID: 12204674 [TBL] [Abstract][Full Text] [Related]
28. Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. González A; Javier Dorta F; Rodriguez G; Brito B; Rodríguez MA; Cabrera A; Díaz-Chico JC; Reyes R; Aguirre-Jaime A; Nicolás Díaz-Chico B Eur J Cancer; 2007 Nov; 43(16):2373-80. PubMed ID: 17728127 [TBL] [Abstract][Full Text] [Related]
29. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329 [TBL] [Abstract][Full Text] [Related]
30. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Damin AP; Frazzon AP; Damin DC; Roehe A; Hermes V; Zettler C; Alexandre CO Cancer Detect Prev; 2006; 30(6):523-9. PubMed ID: 17113725 [TBL] [Abstract][Full Text] [Related]
31. [A polymorphism study of the CYP19 gene in endometrial cancer patients]. Bershteĭn LM; Imianitov EN; Suspitsyn EN; Grigor'ev MIu; Sokolov EP; Togo AV; Khanson KP; Poroshina TE; Gamaiunova VB; Vasil'ev DA; Kovalevskiĭ AIu; Volkov ON Vopr Onkol; 2000; 46(3):302-5. PubMed ID: 10976276 [TBL] [Abstract][Full Text] [Related]
32. [The risk of endometrial cancer appearance and CYP19 and COMT gene polymorphism]. Szyłło K; Smolarz B; Romanowicz-Makowska H; Przybyłowska K; Lewy J; Kulig B Pol Merkur Lekarski; 2007 Mar; 22(129):208-10. PubMed ID: 17682677 [TBL] [Abstract][Full Text] [Related]
33. CYP19 (aromatase) haplotypes and endometrial cancer risk. Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924 [TBL] [Abstract][Full Text] [Related]
34. [Association of polymorphism of genetic markers of CYP19 and CYP17 with sporadic breast cancer]. Artamonov VV; Liubchenko LN; Shabanov MA; Babenko OV; Nemtsova MV; Zaletaev DV Mol Biol (Mosk); 2003; 37(6):975-82. PubMed ID: 14714492 [TBL] [Abstract][Full Text] [Related]
35. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Patel AV; Calle EE; Pavluck AL; Feigelson HS; Thun MJ; Rodriguez C Breast Cancer Res; 2005; 7(6):R1168-73. PubMed ID: 16457697 [TBL] [Abstract][Full Text] [Related]
36. No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Li L; Cicek MS; Casey G; Witte JS Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2280-1. PubMed ID: 15598794 [No Abstract] [Full Text] [Related]
37. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Ahsan H; Whittemore AS; Chen Y; Senie RT; Hamilton SP; Wang Q; Gurvich I; Santella RM Breast Cancer Res; 2005; 7(1):R71-81. PubMed ID: 15642171 [TBL] [Abstract][Full Text] [Related]
38. p53 genotypes and haplotypes associated with risk of breast cancer. Buyru N; Altinisik J; Demokan S; Dalay N Cancer Detect Prev; 2007; 31(3):207-13. PubMed ID: 17574348 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the association between the CYP19 Tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome(PCOS) in Han Chinese women. Hao CF; Zhang N; Qu Q; Wang X; Gu HF; Chen ZJ Neuro Endocrinol Lett; 2010; 31(3):370-4. PubMed ID: 20588246 [TBL] [Abstract][Full Text] [Related]
40. MDR1 C3435T polymorphism in patients with breast cancer. Turgut S; Yaren A; Kursunluoglu R; Turgut G Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]